Correlation Analysis Between Multiple Clinical Indicators and Long COVID
-
摘要:
目的 研究多项临床指标与新冠病毒感染后综合征(long COVID,LC)即长新冠发生发展的关系,并初步探讨这些指标在LC发生中的作用与机制。 方法 收集2023年12月1日至2025年12月1日期间昆明市第三人民医院收治的感染新冠病毒的患者,纳入272例确诊的LC患者设为LC组,115例感染新冠病毒后无并发症的患者设为对照组,通过影像学、血液样本、肺功能检查等方法检测两组患者的临床指标,包括血清炎症指标、免疫功能、MMPs、肺通气功能、肺间质改变等,分析验证上述指标与LC发生发展的关系。通过绘制受试者工作特征(receiver operating characteristic curve,ROC)曲线,评估多项临床指标对LC发病预测的价值,运用二元Logistic回归模型分析多项临床指标与LC进展的关系。 结果 与对照组比较,LC组的炎症指标IL-2(Z = -2.424,P = 0.015)、IL-6(Z = -9.939,P < 0.001)、IL-10(Z = -2.316,P = 0.023),特殊指标MMP-1(Z = -2.473,P = 0.013)、MMP-7(Z = -2.392,P = 0.017)、MMP-9(Z = -10.173,P < 0.001)及MMP-14(Z = -2.135,P = 0.033)升高。LC组患者的免疫指标CD3(Z = -2.280,P = 0.023)、CD4(Z = -15.316,P < 0.001)低于对照组。二元Logistic回归分析显示,CD4(OR = 0.960,95%CI:0.938~0.982,P < 0.001)与LC发生呈负向关联,MMP-9(OR = 1.189,95%CI:1.051~1.345,P = 0.006)和IL-6(OR = 1.112,95%CI:1.038~1.191,P = 0.003)与LC发生呈正向关联。ROC曲线分析显示,CD4、IL-6和MMP-9的AUC分别为0.992(95%CI:0.978~0.998)、0.827(95%CI:0.787~0.867)和0.912(95%CI:0.880~0.945),联合模型的AUC为0.999(95%CI:0.998~1.000),均P < 0.001。 结论 CD4下降、IL-6和MMP-9升高与LC的发生发展紧密相关,联合检测CD4、IL-6、MMP-9,根据结果变化可以判断LC后续进展、疾病演变,是临床预判LC的有效指标。 -
关键词:
- 基质金属蛋白酶 /
- 新冠病毒感染后综合征 /
- 免疫功能 /
- 炎症指标
Abstract:Objective To investigate the correlation between multiple clinical indicators and the occurrence and progression of post-COVID-19 syndrome (Long COVID, LC), and to preliminarily explore the roles and mechanisms of these indicators in the development of LC. Methods Patients with COVID-19 infection admitted to the Third People's Hospital of Kunming from December 1, 2023 to December 1, 2025 were enrolled. A total of 272 patients with confirmed LC were designated as the LC group, and 115 patients without complications after CoVID-19 infection were designated as the control group. Clinical indicators of the two groups were measured by imaging, blood sampling, pulmonary function testing, and other methods, including serum inflammatory indicators, immune function, matrix metalloproteinases (MMPs), pulmonary ventilation function, and pulmonary interstitial changes, to analyze and verify the relationship between the above indicators and the occurrence and development of LC. Receiver operating characteristic (ROC) curves were plotted to evaluate the predictive value of multiple clinical indicators for LC onset, and a binary logistic regression model was used to analyze the relationship between multiple clinical indicators and LC progression. Results Compared with the control group, the inflammatory indicators IL-2 (Z = -2.424, P = 0.015), IL-6 (Z = -9.939, P < 0.001), and IL-10 (Z = -2.316, P = 0.023), as well as the special indicators MMP-1 (Z = -2.473, P = 0.013), MMP-7 (Z = -2.392, P = 0.017), MMP-9 (Z = -10.173, P < 0.001), and MMP-14 (Z = -2.135, P = 0.033), were elevated in the LC group. The immune indicators CD3 (Z = -2.280, P = 0.023) and CD4 (Z = -15.316, P < 0.001) of patients in the LC group were lower than those in the control group. Binary logistic regression analysis showed that CD4(OR = 0.960, 95%CI: 0.938~0.982, P < 0.001) was negatively correlated with the occurrence of LC, whereas MMP-9 (OR = 1.189, 95%CI: 1.051~1.345, P = 0.006) and IL-6 (OR = 1.112, 95%CI: 1.038~1.191, P = 0.003) were positively correlated with the occurrence of LC. ROC curve analysis showed that the AUCs of CD4, IL-6 and MMP-9 were 0.992 (95%CI: 0.978~0.998), 0.827 (95%CI: 0.787~0.867) and 0.912 (95%CI: 0.880~0.945), respectively, and the AUC of the combined model was 0.999 (95%CI: 0.998~1.000), all with P < 0.001. Conclusion Decreased CD4 and elevated IL-6 and MMP-9 are closely associated with the occurrence and progression of LC. Combined detection of CD4, IL-6 and MMP-9 can be used to determine the subsequent progression and disease evolution of LC based on changes in the results, serving as effective indicators for clinical prediction of LC. -
表 1 血清检测指标分类
Table 1. Classification of serum test indicators
检测类别 检测指标(含缩写) 炎症指标 超敏C反应蛋白(HsCRP)、降钙素原(PCT)、血清淀粉样蛋白A(SAA)、干扰素-α、γ(IFN-α、IFN-γ)、
白细胞介素-1β、2、5、6、8、10、12P70、17(IL-1β、IL-2、IL-5、IL-6、IL-8、IL-10、IL-12P70、IL-17)基质金属蛋白酶(MMPs) MMP-1、MMP-2、MMP-3、MMP-4、MMP-5、MMP-6、MMP-7、MMP-8、MMP-9、MMP-10、
MMP-11、MMP-12、MMP-13、MMP-14免疫功能 免疫球蛋白A、E、G、M(IgA、IgE、IgG、IgM)、CD3、CD4、CD8 表 2 一般资料比较[($ \bar x \pm s $)/n(%)]
Table 2. Comparison of general data [($ \bar x \pm s $)/n(%)]
指标 LC组
(n = 272)对照组
(n = 115)t/χ2 P 年龄(岁) 50.34 ± 14.55 47.87 ± 11.41 3.851 0.208 性别 男 149 59 0.397 0.531 女 123 56 咳嗽≥4周 有 175 0 135.065 <0.001* 无 97 115 乏力≥90 d 有 174 0 133.662 <0.001* 无 98 115 气促≥90 d 有 146 0 99.123 <0.001* 无 126 115 肺间质性改变 有 46 0 22.072 <0.001* 无 226 115 肺功能改变 有 195 0 166.178 <0.001* 无 77 115 FeNO异常 有 76 40 1.802 0.179 无 196 75 *P < 0.05。 表 3 血清炎症指标在两组间的差异分析[M(Q1,Q3)]
Table 3. Comparison of serum inflammatory indicators between the two groups [M(Q1,Q3)]
检测指标 LC组(n = 272) 对照组(n = 115) Z P IFN-ɑ(pg/mL) 2.71(1.84,4.04) 2.62(1.72,4.02) 2.316 0.103 IFN-γ(pg/mL) 2.68(1.93,4.37) 2.73(2.01,4.39) 2.291 0.147 TNF-ɑ(pg/mL) 2.75(1.75,4.21) 2.81(2.03,4.14) 1.235 0.172 IL-1β(pg/mL) 2.91(1.97,4.66) 2.87(1.86,4.62) 1.386 0.213 IL-2(pg/mL) 5.04(2.44,9.09) 4.70(2.48,6.85) −2.424 0.015* IL-5(pg/mL) 5.52(3.49,8.18) 5.61(3.46,8.12) 1.943 0.706 IL-6(pg/mL) 33.62(20.45,53.45) 9.85(4.80,19.49) −9.939 <0.001* IL-8(pg/mL) 3.54(2.14,4.89) 3.45(1.96,4.73) 1.980 0.305 IL-10(pg/mL) 4.46(2.84,6.65) 2.98(2.18,5.59) −2.316 0.023* IL-12P70(pg/mL) 4.33(1.74,7.21) 4.27(1.66,7.25) 0.144 0.464 IL-17(pg/mL) 2.01(1.35,3.71) 1.98(1.34,3.66) 2.875 0.394 CRP(mg/mL) 4.41(1.62,6.03) 2.89(1.57,5.98) 2.126 0.703 PCT(ng/mL) 0.09(0.02,3.16) 0.08(0.02,3.11) 1.647 0.533 SAA(mg/mL) 24.66(5.46,45.71) 23.97(5.52,42.18) 1.597 0.201 *P < 0.05。 表 4 MMPs在两组间的表达[M(Q1,Q3)]
Table 4. Comparison of MMPs between the two groups[M(Q1,Q3)]
检测指标(ng/mL) LC组(n = 272) 对照组(n = 115) Z P MMP-1 91.32(78.34,115.40) 78.23(67.89,112.34) −2.473 0.013* MMP-2 32.25(23.32,40.98) 33.78(17.87,49.67) −0.894 0.371 MMP-3 11.06(6.98,14.01) 10.19(6.59,15.42) 1.224 0.186 MMP-4 24.43(18.89,29.32) 21.93(16.87,29.78) −0.609 0.542 MMP-5 21.81(11.84,44.04) 20.52(12.52,43.12) 1.386 0.223 MMP-6 39.20(22.67,51.61) 38.68(21.21,50.09) 1.382 0.211 MMP-7 28.79(21.45,37.44) 23.45(19.82,37.23) −2.392 0.017* MMP-8 35.48(23.07,55.39) 34.72(23.74,56.95) 1.607 0.164 MMP-9 59.78 (43.21,68.77) 34.21(27.54,44.39) −10.173 <0.001* MMP-10 289.08(62.11,565,23) 277.12(59.78,553.21) 1.653 0.216 MMP-11 245.11(143.10,355.76) 238.32(155.71,342.21) 1.533 0.167 MMP-12 7.45(2.93,11.50) 6.78(3.02,12.32) 1.279 0.131 MMP-13 149.12(67.82,267.11) 151.11(71.22,273.05) 1.791 0.231 MMP-14 78.65(59.78,82.98) 69.45(49.78,80.34) −2.135 0.033* *P < 0.05。 表 5 免疫功能检测在两组之间的差异[M(Q1,Q3)]
Table 5. Comparison of immune function indicators between the two groups [M(Q1,Q3)]
检测指标 LC组(n = 272) 对照组(n = 115) Z P IgA(g/L) 1.34(0.84,2.58) 1.36(0.91,2.62) 0.687 0.673 IgE(IU/mL) 65.50(38.86,83.56) 66.59(37.90,84.73) 0.979 0.241 IgG(g/L) 9.52(7.87,16.43) 9.58(8.34,16.68) 0.166 0.804 IgM(g/L) 1.19(0.98,2.11) 1.16(0.92,2.17) 0.224 0.894 CD3(个/ul) 788.40(716.65.6,808.45) 802.10(727.95,820.05) −2.280 0.023* CD4(个/ul) 344.60(313.20,368.90) 712.50(642.80,860.40) −15.316 <0.001* CD8(个/ul) 376.20(322.67,921.61) 377.68(312.21,938.09) 1.65 0.098 *P < 0.05。 表 6 LC患者的影响因素二元Logistic回归分析
Table 6. Binary logistic regression analysis of influencing factors of LC
影响因素 B SE Wald OR 95%CI P CD4 −0.041 0.012 12.405 0.960 0.938~0.982 <0.001* MMP-9 0.173 0.063 7.596 1.189 1.051~1.345 0.006* IL-6 0.106 0.035 9.044 1.112 1.038~1.191 0.003* *P < 0.05。 表 7 多项指标预测LC发生的ROC曲线分析
Table 7. ROC curve analysis of multiple indicators for predicting LC
检测项目 AUC AUC的95%CI P 截断值 灵敏度 特异度 正确指数 CD4 0.992 0.987–0.998 <0.001* 512.45 0.963 1.000 0.963 IL-6 0.827 0.787–0.867 <0.001* 55.54 0.673 0.922 0.595 MMP-9 0.912 0.880–0.945 <0.001* 21.13 0.882 0.817 0.700 联合预测模型 0.999 0.999–1.000 <0.001* 0.833 0.985 0.991 0.977 *P < 0.05。 -
[1] Davis H E, McCorkell L, Vogel J M, et al. Long COVID: Major findings, mechanisms and recommendations[J]. Nat Rev Microbiol, 2023, 21(3): 133-146. doi: 10.1038/s41579-022-00846-2 [2] 张允旭, 翟萍, 刘琪, 等. 新型冠状病毒感染后综合征的研究进展[J]. 中国康复理论与实践, 2023, 29(9): 1114-1122. [3] Guo M, Shang S, Li M, et al. Understanding autoimmune response after SARS-CoV-2 infection and the pathogenesis/mechanisms of long COVID[J]. Med Rev, 2024, 4(5): 367-383. doi: 10.1515/mr-2024-0013 [4] Castanares-Zapatero D, Chalon P, Kohn L, et al. Pathophysiology and mechanism of long COVID: A comprehensive review[J]. Ann Med, 2022, 54(1): 1473-1487. doi: 10.1080/07853890.2022.2076901 [5] Steyerberg E, Hackmann T, van Calster B, et al. Recent criteria and simple rules agreed often on required sample size for developed clinical prediction models[J]. J Clin Epidemiol, 2026, 199: 112461. doi: 10.1016/j.jclinepi.2026.112461 [6] Bhat E A, Khan J, Sajjad N, et al. SARS-CoV-2: Insight in genome structure, pathogenesis and viral receptor binding analysis–An updated review[J]. Int Immunopharmacol, 2021, 95: 107493. doi: 10.1016/j.intimp.2021.107493 [7] Tsilingiris D, Vallianou N G, Karampela I, et al. Laboratory findings and biomarkers in long COVID: What do we know so far? insights into epidemiology, pathogenesis, therapeutic perspectives and challenges[J]. Int J Mol Sci, 2023, 24(13): 10458. doi: 10.3390/ijms241310458 [8] 陈彰, 孙天生, 唐昊. 以呼吸系统为重点的长新冠综合征的研究进展[J]. 临床肺科杂志, 2025, 30(1): 109-114. doi: 10.3969/j.issn.1009-6663.2025.01.019 [9] Cadamuro M, Lasagni A, Radu C M, et al. Procoagulant phenotype of virus-infected pericytes is associated with portal thrombosis and intrapulmonary vascular dilations in fatal COVID-19[J]. J Hepatol, 2024, 81(5): 872-885. doi: 10.1016/j.jhep.2024.06.014 [10] 王荟, 吕巧怡, 赵杨静, 等. 血管紧张素转换酶2在SARS-CoV-2感染中的作用机制研究进展[J]. 江苏大学学报(医学版), 2021, 31(1): 88-92. doi: 10.13312/j.issn.1671-7783.y200123 [11] Yelin D, Ghantous N, Awwad M, et al. Pulmonary diffusing capacity among individuals recovering from mild to moderate COVID-19: A cross-sectional study[J]. Sci Rep, 2024, 14(1): 26767. doi: 10.1038/s41598-024-74404-6 [12] Yin K, Peluso M J, Luo X, et al. Long COVID manifests with T cell dysregulation, inflammation and an uncoordinated adaptive immune response to SARS-CoV-2[J]. Nat Immunol, 2024, 25(2): 218-225. doi: 10.1038/s41590-023-01724-6 [13] Holms R. Long COVID (PASC) is maintained by a self-sustaining pro-inflammatory TLR4/RAGE-loop of S100A8/A9 > TLR4/RAGE signalling, inducing chronic expression of IL-1b, IL-6 and TNFa: Anti-inflammatory ezrin peptides as potential therapy[J]. Immuno, 2022, 2(3): 512-533. doi: 10.3390/immuno2030033 [14] Zhang H, Wu T. CD4+T, CD8+T counts and severe COVID-19: A meta-analysis[J]. J Infect, 2020, 81(3): e82-e84. doi: 10.1016/j.jinf.2020.06.036 [15] Sampaio Moura N, Schledwitz A, Alizadeh M, et al. Matrix metalloproteinases as biomarkers and therapeutic targets in colitis-associated cancer[J]. Front Oncol, 2024, 13: 1325095. doi: 10.3389/fonc.2023.1325095 [16] Tanase D M, Valasciuc E, Anton I B, et al. Matrix metalloproteinases: Pathophysiologic implications and potential therapeutic targets in cardiovascular disease[J]. Biomolecules, 2025, 15(4): 598. doi: 10.3390/biom15040598 [17] 王文婷, 徐寒梅, 李梦玮, 等. 基质金属蛋白酶及整合素在肺纤维化中的作用[J]. 药物生物技术, 2023, 30(2): 180-185. doi: 10.19526/j.cnki.1005-8915.20230214 [18] 张楠, 魏少鹏, 雷连成, 等. T细胞在SARS-CoV-2感染和免疫逃逸中作用的研究进展[J]. 病毒学报, 2025, 41(4): 1306-1318. doi: 10.13242/j.cnki.bingduxuebao.004630 [19] Wang L, Peng H Y, Pham A, et al. T cell response to SARS-CoV-2 coinfection and comorbidities[J]. Pathogens, 2023, 12(2): 321. doi: 10.3390/pathogens12020321 [20] Phetsouphanh C, Darley D R, Wilson D B, et al. Immunological dysfunction persists for 8 months following initial mild-to-moderate SARS-CoV-2 infection[J]. Nat Immunol, 2022, 23(2): 210-216. doi: 10.1038/s41590-021-01113-x [21] 王利娟, 李华, 魏霞. 新型冠状病毒感染患者免疫功能与胸部CT表现之间的关系[J]. 临床肺科杂志, 2025, 30(1): 1-7. doi: 10.3969/j.issn.1009-6663.2025.01.001 -
下载: